首页> 外文期刊>Clinical and experimental allergy : >Interleukin-25 promotes basic fibroblast growth factor expression by human endothelial cells through interaction with IL-17RB, but not IL-17RA
【24h】

Interleukin-25 promotes basic fibroblast growth factor expression by human endothelial cells through interaction with IL-17RB, but not IL-17RA

机译:白细胞介素25通过与IL-17RB而非IL-17RA相互作用促进人内皮细胞碱性成纤维细胞生长因子表达

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Background: Unlike other IL-17 family members, the Th2-derived cytokine IL-25 (IL-17E) induces (promotes) Th2 responses. One or both of the two receptors for IL-25 (IL-17RA, IL-17RB) is expressed on inflammatory cells and tissue structural cells, suggesting that in addition to promoting Th2-type inflammation IL-25 may also act on structural cells at sites of Th2-type inflammation such as in the asthmatic bronchial mucosa to promote remodelling changes. Objective: Our previous studies showed elevated expression of IL-25 and IL-17RB immunoreactivity in asthmatic airways with co-localization of the latter to endothelial cells. We therefore hypothesized that IL-25 acts on endothelial cells through this receptor to induce production of the key angiogenic and remodelling cytokine basic fibroblast growth factor (bFGF). Methods: Polymerase chain reaction (PCR) immunocytochemistry/immunohistochemistry and ELISA were employed to detect expression of IL-17RB, IL-17RA and bFGF by human vascular endothelial cells (HUVEC) and immunoreactivity for IL-25 and bFGF in asthmatic bronchial biopsies. Receptor-blocking antibodies, PCR and an in vitro angiogenesis assay were used to investigate whether IL-25 acts on IL-17RB or IL-17RA to induce bFGF expression and angiogenesis. PCR was also employed to investigate the signalling pathways involved in IL-25-mediated bFGF expression. Results: HUVEC constitutively expressed IL-17RB, IL-17RA and bFGF. Production of the latter was further increased by IL-25, but attenuated after blockade of the IL-17RB, but not the IL-17RA receptor. Neutralization of endogenous VEGF and bFGF completely abrogated IL-25-induced angiogenesis which was also inhibited by blocking IL-17RB, but not IL-17RA. The PI3K-specific inhibitor LY294002 also completely attenuated IL-25-induced bFGF expression. Immunoreactivity for IL-25 and bFGF was elevated in the asthmatic bronchial mucosa and the expression of each correlated with the other. Conclusions and Clinical Relevance: Our data support the hypothesis that IL-25 contributes to elevated bFGF in asthmatic airways by acting on the endothelial cell IL-17RB receptor through PI3K-signalling pathways. Targeting the pathways might benefit therapy of airways remodelling.
机译:背景:与其他IL-17家族成员不同,Th2衍生的细胞因子IL-25(IL-17E)诱导(促进)Th2反应。 IL-25的两种受体(IL-17RA,IL-17RB)中的一种或两种在炎症细胞和组织结构细胞上表达,这表明除了促进Th2型炎症外,IL-25还可在以下部位作用于结构细胞: Th2型炎症的位点,例如在哮喘支气管粘膜中促进重塑的改变。目的:我们先前的研究显示哮喘气道中IL-25和IL-17RB免疫反应性的表达升高,而后者与内皮细胞共定位。因此,我们假设IL-25通过该受体作用于内皮细胞,以诱导关键血管生成和重塑细胞因子碱性成纤维细胞生长因子(bFGF)的产生。方法:采用聚合酶链反应(PCR)免疫细胞化学/免疫组化和ELISA法检测人支气管内皮细胞(HUVEC)中IL-17RB,IL-17RA和bFGF的表达以及哮喘支气管活检组织中IL-25和bFGF的免疫反应性。受体封闭抗体,PCR和体外血管生成试验用于研究IL-25是否作用于IL-17RB或IL-17RA以诱导bFGF表达和血管生成。 PCR还用于研究IL-25介导的bFGF表达中涉及的信号传导途径。结果:HUVEC组成性表达IL-17RB,IL-17RA和bFGF。 IL-25进一步增加了后者的产量,但在阻断IL-17RB而非IL-17RA受体后减弱了产量。内源性VEGF和bFGF的中和作用完全消除了IL-25诱导的血管生成,这也被阻断IL-17RB抑制,但未被IL-17RA抑制。 PI3K特异性抑制剂LY294002也完全减弱了IL-25诱导的bFGF表达。在哮喘支气管粘膜中,IL-25和bFGF的免疫反应性升高,并且两者的表达相互关联。结论与临床意义:我们的数据支持以下假设:IL-25通过PI3K信号通路作用于内皮细胞IL-17RB受体,从而导致哮喘气道bFGF升高。靶向途径可能有益于气道重塑的治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号